WEX proxy fight escalates as ISS, Glass Lewis back two Impactive nominees

Institutional Shareholder Services, Glass Lewis, and Egan-Jones have issued recommendations supporting two Impactive Capital nominees to WEX Inc.'s board, a rare triple endorsement that places the Portland-based payments processor under meaningful governance pressure. The advisory firms, whose recommendations collectively influence proxy votes covering more than $40 trillion in assets under management, advised shareholders to vote against certain company-backed directors at WEX's upcoming annual meeting.

WEX operates a $7.2 billion market-cap payments infrastructure business serving fleet, travel, and healthcare verticals. Impactive Capital, a New York activist fund managing approximately $6 billion, disclosed a stake in WEX earlier this year and nominated four directors, arguing the board lacks operational depth in payments technology and has overseen underperformance relative to peers. The company's stock has lagged the S&P 500 by 18 percentage points over the past three years, closing Friday at $147.32 per share. ISS recommended shareholders vote for two of Impactive's four nominees, citing concerns about board refreshment and strategic oversight. Glass Lewis issued a similar split endorsement, while Egan-Jones backed the same two candidates, creating a coordinated advisory wall against management's slate.

The proxy advisory convergence matters because it shifts the default institutional vote. Passive managers and smaller institutions often follow ISS and Glass Lewis recommendations without independent review, meaning WEX management now faces a structural voting disadvantage. The two Impactive nominees receiving unanimous advisory backing bring payments fintech and software infrastructure experience from prior roles at Fiserv and Block. WEX's argument that its incumbent directors provide sufficient industry knowledge has not persuaded the advisory firms, which explicitly noted in their reports that the board's median tenure of 6.8 years has not translated into outperformance. The company generates roughly $2.1 billion in annual revenue but trades at 14.2x forward EBITDA, below the 16.5x median for payments processors with comparable scale.

The vote outcome will determine whether WEX accelerates a portfolio review that Impactive has pressed for since January. The activist fund has argued WEX should divest its health payments business, which contributes $480 million in revenue but operates at lower margins than the core fleet and corporate payments segments. Management has resisted a full sale, instead pursuing operational improvements and technology integration. If the two Impactive nominees win seats, the board composition shifts enough to force a strategic review committee, likely before the September quarter earnings call. Allocators watching this name should track institutional voting disclosures filed in the five days before the annual meeting, expected in late May or early June, as well as any pre-meeting settlement talks that could result in a negotiated board expansion.

WEX reports first-quarter earnings on April 24, two weeks before the expected proxy vote. The company has guided to $2.58 billion in full-year revenue and $15.80 in adjusted earnings per share, implying 11 percent revenue growth but flat margin expansion. If results miss and the proxy vote follows days later, the dual pressure could accelerate a CEO or CFO change, a scenario neither side has publicly discussed but which Glass Lewis flagged as a possible outcome in its recommendation report.